Humacyte (NASDAQ:HUMA) Given Speculative Buy Rating at Benchmark

Benchmark reissued their speculative buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note released on Tuesday,Benzinga reports.

Several other research analysts have also recently weighed in on HUMA. BTIG Research reduced their price target on Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Friday, March 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Finally, UBS Group reissued a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Humacyte has a consensus rating of “Moderate Buy” and a consensus target price of $7.71.

Humacyte Price Performance

Shares of HUMA opened at $0.61 on Tuesday. The business’s 50-day moving average is $1.02 and its two-hundred day moving average is $1.27. The company has a market capitalization of $113.62 million, a P/E ratio of -3.03 and a beta of 1.89. Humacyte has a fifty-two week low of $0.55 and a fifty-two week high of $2.93. The company has a debt-to-equity ratio of 20.08, a quick ratio of 0.90 and a current ratio of 3.69.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). Humacyte had a negative return on equity of 990.48% and a negative net margin of 1,998.87%.The business had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $1.35 million. Research analysts predict that Humacyte will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP increased its stake in shares of Humacyte by 5,308.2% in the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after acquiring an additional 2,590,394 shares during the last quarter. Millennium Management LLC boosted its position in shares of Humacyte by 129.5% during the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock valued at $2,528,000 after acquiring an additional 1,485,152 shares during the last quarter. UBS Group AG boosted its position in shares of Humacyte by 48.8% during the 4th quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock valued at $2,862,000 after acquiring an additional 976,275 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Humacyte by 33.4% in the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after purchasing an additional 738,142 shares during the period. Finally, Barclays PLC grew its holdings in shares of Humacyte by 298.7% in the fourth quarter. Barclays PLC now owns 729,469 shares of the company’s stock valued at $701,000 after purchasing an additional 546,491 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.